Reed I Ayabe1, Raja R Narayan2, Samantha M Ruff1, Michael M Wach1, Winifred Lo1, Pieter M H Nierop3, Seth M Steinberg4, R Taylor Ripley1, Jeremy L Davis1, Bas G Koerkamp3, Michael I D'Angelica2, T Peter Kingham2, William R Jarnagin2, Jonathan M Hernandez5. 1. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2. Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands. 4. Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 5. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: jonathan.hernandez@nih.gov.
Abstract
BACKGROUND: Adrenocortical carcinoma (ACC) is an aggressive malignancy that frequently metastasizes to the liver. Given the limitations of systemic therapy in this setting, we sought to determine characteristics associated with a two-fold increase in survival with resection/ablation compared to that reported with chemotherapy alone (∼12 months). METHODS: Patients who underwent resection/ablation at our institutions for ACC liver metastases were identified. Those who survived 12-24 months after metastasectomy were excluded, as the aim was to characterize patients who most clearly benefited from these procedures. Clinicopathologic and treatment characteristics were assessed for associations with survival. RESULTS: Sixty-two patients met inclusion criteria, of whom 44 survived >24 months and 18 survived <12 months. Patients with extended survival were less likely to have functioning tumors (p = 0.047), had fewer liver metastases (p = 0.047), and a longer disease-free interval (DFI) (median 17.6 vs 2.3 months, p < 0.0001). On multivariable analysis, DFI (OR = 1.33, 95% CI = 1.12-1.58) and non-functioning tumor (OR = 0.13, 95% CI = 0.13-0.56) were independently associated with prolonged survival. CONCLUSION: Metastasectomy/ablation should be considered for patients with ACC liver metastases. DFI and tumor functional status may be useful in selecting optimal candidates for these procedures. Published by Elsevier Ltd.
BACKGROUND:Adrenocortical carcinoma (ACC) is an aggressive malignancy that frequently metastasizes to the liver. Given the limitations of systemic therapy in this setting, we sought to determine characteristics associated with a two-fold increase in survival with resection/ablation compared to that reported with chemotherapy alone (∼12 months). METHODS:Patients who underwent resection/ablation at our institutions for ACC liver metastases were identified. Those who survived 12-24 months after metastasectomy were excluded, as the aim was to characterize patients who most clearly benefited from these procedures. Clinicopathologic and treatment characteristics were assessed for associations with survival. RESULTS: Sixty-two patients met inclusion criteria, of whom 44 survived >24 months and 18 survived <12 months. Patients with extended survival were less likely to have functioning tumors (p = 0.047), had fewer liver metastases (p = 0.047), and a longer disease-free interval (DFI) (median 17.6 vs 2.3 months, p < 0.0001). On multivariable analysis, DFI (OR = 1.33, 95% CI = 1.12-1.58) and non-functioning tumor (OR = 0.13, 95% CI = 0.13-0.56) were independently associated with prolonged survival. CONCLUSION: Metastasectomy/ablation should be considered for patients with ACC liver metastases. DFI and tumor functional status may be useful in selecting optimal candidates for these procedures. Published by Elsevier Ltd.
Authors: Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides Journal: J Surg Oncol Date: 2016-09-16 Impact factor: 3.454
Authors: A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Nicole M Datrice; Russell C Langan; R Taylor Ripley; Clinton D Kemp; Seth M Steinberg; Bradford J Wood; Steven K Libutti; Tito Fojo; David S Schrump; Itzhak Avital Journal: J Surg Oncol Date: 2011-12-20 Impact factor: 3.454
Authors: Martin Fassnacht; Massimo Terzolo; Bruno Allolio; Eric Baudin; Harm Haak; Alfredo Berruti; Staffan Welin; Carmen Schade-Brittinger; André Lacroix; Barbara Jarzab; Halfdan Sorbye; David J Torpy; Vinzenz Stepan; David E Schteingart; Wiebke Arlt; Matthias Kroiss; Sophie Leboulleux; Paola Sperone; Anders Sundin; Ilse Hermsen; Stefanie Hahner; Holger S Willenberg; Antoine Tabarin; Marcus Quinkler; Christelle de la Fouchardière; Martin Schlumberger; Franco Mantero; Dirk Weismann; Felix Beuschlein; Hans Gelderblom; Hanneke Wilmink; Monica Sender; Maureen Edgerly; Werner Kenn; Tito Fojo; Hans-Helge Müller; Britt Skogseid Journal: N Engl J Med Date: 2012-05-02 Impact factor: 91.245
Authors: Martin Fassnacht; Alfredo Berruti; Eric Baudin; Michael J Demeure; Jill Gilbert; Harm Haak; Matthias Kroiss; David I Quinn; Elizabeth Hesseltine; Cristina L Ronchi; Massimo Terzolo; Toni K Choueiri; Srinivasu Poondru; Tanya Fleege; Ramona Rorig; Jihong Chen; Andrew W Stephens; Francis Worden; Gary D Hammer Journal: Lancet Oncol Date: 2015-03-18 Impact factor: 41.316
Authors: R Taylor Ripley; Clinton D Kemp; Jeremy L Davis; Russell C Langan; Richard E Royal; Steven K Libutti; Seth M Steinberg; Bradford J Wood; Udai S Kammula; Tito Fojo; Itzhak Avital Journal: Ann Surg Oncol Date: 2011-02-08 Impact factor: 5.344
Authors: Johannes Baur; Tjark-Ole Büntemeyer; Felix Megerle; Timo Deutschbein; Christine Spitzweg; Marcus Quinkler; Peter Nawroth; Matthias Kroiss; Christoph-Thomas Germer; Martin Fassnacht; Ulrich Steger Journal: BMC Cancer Date: 2017-08-04 Impact factor: 4.430
Authors: Winifred Lo; Reed I Ayabe; Christine M Kariya; Meghan L Good; Seth M Steinberg; Jeremy L Davis; Robert T Ripley; Jonathan M Hernandez Journal: J Surg Oncol Date: 2019-12-06 Impact factor: 2.885
Authors: Sarah N Fuller; Ahmad Shafiei; David J Venzon; David J Liewehr; Michal Mauda Havanuk; Maran G Ilanchezhian; Maureen Edgerly; Victoria L Anderson; Elliot B Levy; Choung D Hoang; Elizabeth C Jones; Karlyne M Reilly; Brigitte C Widemann; Bradford J Wood; Hadi Bagheri; Jaydira Del Rivero Journal: Curr Oncol Date: 2021-11-01 Impact factor: 3.677